Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 7.5% - What's Next?

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) shares rose 7.5% during mid-day trading on Wednesday . The company traded as high as $17.16 and last traded at $16.97. Approximately 584,887 shares changed hands during trading, a decline of 31% from the average daily volume of 850,763 shares. The stock had previously closed at $15.79.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on GPCR shares. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Structure Therapeutics in a research report on Thursday, December 19th. Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $50.00 target price on the stock. William Blair assumed coverage on Structure Therapeutics in a report on Friday, February 28th. They issued an "outperform" rating for the company. Finally, JMP Securities restated a "market outperform" rating and set a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Structure Therapeutics has an average rating of "Buy" and an average target price of $81.29.

Structure Therapeutics Stock Up 7.9 %

The company has a 50 day moving average of $21.52 and a 200 day moving average of $29.57. The firm has a market cap of $875.63 million, a price-to-earnings ratio of -20.63 and a beta of -1.35.

Remove Ads

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. As a group, equities research analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in GPCR. ANTIPODES PARTNERS Ltd lifted its position in shares of Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after purchasing an additional 553 shares during the last quarter. GAMMA Investing LLC raised its stake in Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after buying an additional 1,122 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Structure Therapeutics during the 4th quarter worth approximately $34,000. FNY Investment Advisers LLC acquired a new position in shares of Structure Therapeutics in the 4th quarter worth approximately $40,000. Finally, Virtus ETF Advisers LLC increased its holdings in shares of Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after acquiring an additional 455 shares during the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.